Advertisement
ABBV vs ALNY
Which Stock Would AI Choose? AbbVie (ABBV) vs. Alnylam Pharmaceuticals (ALNY) Stock Comparison
Key Takeaways
- ABBV has demonstrated stability with YTD gains of approximately 1.5% and a 6.1% rise since its latest earnings, supported by strong immunology sales and a high dividend yield of 3%.
- ALNY shows robust 1-year returns around 29-31% but lags YTD at -19%, reflecting volatility amid partnerships and revenue growth from RNAi therapies like Amvuttra.
- ABBV boasts a larger market cap (~$407B) and lower beta (0.33), indicating reduced risk compared to ALNY's ~$43B cap and higher volatility.
- Recent catalysts include ABBV's positive Phase 3 data for Skyrizi in Crohn's and ALNY's $1.23B cardiovascular deal with Tenaya.
- AI robots on Tickeron favor trend consistency, where ABBV edges out in recent momentum and stability versus ALNY's growth potential.
Introduction
This stock comparison examines ABBV and ALNY, two biopharmaceutical leaders in distinct niches: AbbVie's diversified immunology and oncology portfolio versus Alnylam Pharmaceuticals' pioneering RNAi therapeutics for rare genetic diseases. Both operate in the high-stakes biotech sector, where innovation drives relative performance and market positioning. Traders seeking stability and dividends may lean toward ABBV, while growth-oriented investors eye ALNY's pipeline momentum. Recent market activity highlights contrasts in sentiment, earnings beats, and strategic deals, aiding informed decisions on stock comparison and potential rotations.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a global research-based biopharmaceutical firm specializing in immunology (Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Botox), aesthetics, and eye care. With ~57,000 employees across 70+ countries, it focuses on innovative therapies for complex health issues. In recent market activity, ABBV shares rose about 6.1% post-Q4 2025 earnings, where adjusted EPS of $2.71 beat estimates, driven by immunology growth and solid cash flows. YTD performance stands at +1.5%, with 1-year returns near 13%, outperforming in stability amid broader biotech volatility. Sentiment benefits from positive Phase 3 results for risankizumab in Crohn's disease and sustained Humira contributions, though valuation concerns persist with a P/E of 97. Recent weeks saw shares test 52-week highs near $245, supported by a 3% dividend yield and analyst targets averaging $249.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals Inc. (ALNY) pioneers RNA interference (RNAi) therapeutics, targeting genetically defined diseases with drugs like Amvuttra (vutrisiran) for ATTR amyloidosis, Givlaari, and Oxlumo. Headquartered in Cambridge, MA, the company emphasizes silencing disease-causing genes through innovative RNAi platforms. Recent performance reflects mixed signals: Q4 2025 revenues hit $1.1B (up 85% YoY) on Amvuttra demand post-label expansion, with EPS of $1.25 beating estimates, yet shares dipped on guidance. YTD returns are -19%, contrasting 29% 1-year gains, with heightened volatility (recent 30% 90-day decline). Key developments include a $1.23B cardiovascular pact with Tenaya Therapeutics and Canadian reimbursement for Amvuttra, bolstering TTR franchise growth toward $3B annual revenues. Trading around $321 (52-week range $206-$496), analysts see upside to $457 amid pipeline advances.
Trending AI Robots
Tickeron's Trending AI Robots page curates the platform's top-performing AI trading bots from hundreds available, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots are selected based on real-time adaptability to current market conditions, showcasing superior metrics like annualized returns up to +218% (e.g., USAR/SMR/CIFR bot), win rates from 53% to 95%, and diverse strategies including trend-following, volatility plays on 2x/3x ETFs, and sector-specific signals (aerospace, semis, energy) over timeframes like 5min to 60min. With virtual agents for risk management and brokerage integration, they cater to various styles without minimum balances. Explore these high-conviction options to enhance your trading edge in volatile biotech environments like ABBV and ALNY.
Head-to-Head Comparison
ABBV and ALNY diverge in business models: AbbVie's established, diversified revenue from blockbusters offers stability (beta 0.33, $407B cap), while Alnylam's RNAi focus drives high-growth but volatile paths tied to rare disease approvals. Growth drivers contrast—ABBV via immunology expansions (Skyrizi/Rinvoq) versus ALNY's Amvuttra surge (151% TTR growth). Recent momentum favors ABBV's post-earnings uptrend (+6% short-term, YTD positive) over ALNY's YTD pullback despite 1-year outperformance. Risk factors include ABBV's patent cliffs and high P/E (97), against ALNY's clinical dependencies and share weakness post-guidance. Sector exposure aligns in biotech, but sentiment tilts to ABBV's dividends and cash flows amid ALNY's partnerships signaling pipeline upside. Trade-offs pit ABBV's reliability against ALNY's transformative potential.
Tickeron AI Verdict
Tickeron's AI currently favors ABBV for its trend consistency, post-earnings momentum, lower volatility, and relative stability in recent market activity. Observable factors like YTD gains, dividend support, and immunology catalysts position it probabilistically stronger short-term versus ALNY's growth trajectory amid YTD weakness, though ALNY holds appeal for higher-risk, pipeline-driven upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and ALNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileALNY’s FA Score has 1 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- ALNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while ALNY’s TA Score has 2 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- ALNY’s TA Score: 2 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while ALNY (@Biotechnology) price change was -3.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
ALNY is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | ALNY | ABBV / ALNY | |
| Capitalization | 369B | 41.3B | 893% |
| EBITDA | 17.6B | 631M | 2,789% |
| Gain YTD | -7.305 | -22.127 | 33% |
| P/E Ratio | 87.92 | 132.90 | 66% |
| Revenue | 61.2B | 3.71B | 1,648% |
| Total Cash | N/A | 2.91B | - |
| Total Debt | 67.5B | 1.28B | 5,282% |
ABBV | ALNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 53 | |
SMR RATING 1..100 | 1 | 15 | |
PRICE GROWTH RATING 1..100 | 55 | 62 | |
P/E GROWTH RATING 1..100 | 40 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALNY (94) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than ALNY’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALNY (53) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than ALNY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as ALNY (15) in the Biotechnology industry. This means that ABBV’s stock grew similarly to ALNY’s over the last 12 months.
ABBV's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as ALNY (62) in the Biotechnology industry. This means that ABBV’s stock grew similarly to ALNY’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ABBV | ALNY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | N/A |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 65% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 72% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 51% | 3 days ago 69% |
| Advances ODDS (%) | 11 days ago 57% | 6 days ago 76% |
| Declines ODDS (%) | 7 days ago 48% | 3 days ago 66% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 71% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHC | 51.00 | 0.82 | +1.63% |
| Schwab International Small-Cap Eq ETF™ | |||
| LGHT | 9.02 | 0.14 | +1.60% |
| Langar Global HealthTech ETF | |||
| SEPT | 36.30 | 0.22 | +0.62% |
| AllianzIM US Equity Buffer10 Sep ETF | |||
| LQDH | 92.82 | 0.05 | +0.05% |
| iShares Interest Rate Hedged Corp Bd ETF | |||
| RITPF | 29.00 | N/A | N/A |
| RIT Capital Partners Plc. | |||